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Abstract
Brain tumors are now the leading cause of cancer-related deaths in children under age 15. Malignant
gliomas are, for all practical purposes, incurable and new therapeutic approaches are desperately
needed. One emerging strategy is to use the tumor tracking capacity inherent in many stem cell
populations to deliver therapeutic agents to the brain cancer cells. Current limitations of the stem
cell therapy strategy include that stem cells are treated as a single entity and lack of uniform
technology is adopted for selection of clinically relevant sub-populations of stem cells. Specifically,
therapeutic success relies on the selection of a clinically competent stem cell population based on
their capacity of targeting brain tumors. A novel and generalizable organotypic slice platform to
evaluate stem cell potential for targeting pediatric brain tumors is proposed to fill the gap in the
current work flow of stem cell-based therapy. The organotypic slice platform has advantages of
being mimic in vivo model, easier to manipulate to optimize parameters than in vivo models such as
rodents and primates. This model serves as a framework to address the discrepancy between
anticipated in vivo results and actual in vivo results, a critical barrier to timely progress in the field
of the use of stem cells for the treatment of neurological disorders.
Introduction: current challenges in treatment of 
pediatric brain tumors
Over 1.4 million people in the United States were diag-
nosed with cancer in 2007 and the national cost of the dis-
ease was over $206 billion in 2006, accounting one-thirds
of healthcare dollars (total: $686 billion) spent in the U.S.
[1,2]. An estimated 18,820 new cases of brain cancer was
diagnosed in the United States of America in 2006, and
more than 12,000 would die from the disease (data from
the National Cancer Institute of the United States of
America). Our current forms of therapy for these diseases
are brain surgery followed by administration of toxic
drugs and exposure to radiation, which lead that the
patients face challenges due to both the effects of treat-
ment and potential neurological dysfunction. Overall the
cost of care per patient was $67,887 with accrued mean
monthly health care costs that were 20 times higher than
demographically similar individuals without cancer
($6364 vs. $277)[3].
Primary malignant tumors such as high grade gliomas dif-
fusely migrate into the brain early in the disease course,
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disseminating tumor microsatellites to distant regions of
the central nervous system [4]. These tentacles of tumor
exist interspersed between normal functional tissues.
Complete surgical resection of many malignant brain
tumors is not practical by virtue of their anatomical loca-
tion and the relationship of this diffuse disease relative to
eloquent functional tissue. Adjuvant therapies including
chemotherapy and radiation therapy are often used in
conjunction with surgery for many types of cancer to
attempt eradication of the residual tumor [5]. In malig-
nant brain tumors, however, combined surgical and adju-
vant therapies frequently prove insufficient to eliminate
neoplastic disease as a result of unique characteristics of
CNS anatomy and function as well as and practical limi-
tations concerning biological characteristics of the tumor
[6]. Therefore, despite gross total surgical resection, chem-
otherapy and radiation therapy, neoplastic cells persist
and inevitably give rise to recurrent tumor. The majority
of children with malignant glioma die and survivors are
usually left with lifelong neurological and cognitive disa-
bilities due to the cumulative result of pre-treatment dam-
age arising from the growing tumor, and the deleterious
effects of surgery and adjuvant therapies [7-13]. It is clear
that a new medical approach to brain cancers is needed.
Stem cells may provide the basis for a new approach.
Emerging stem cell therapy of brain tumors
The lack of efficacy for conventional treatments of malig-
nant brain tumors can be readily appreciated by the grave
prognosis of for malignant gliomas, brainstem gliomas. In
contrast to pediatric hematological malignancies, mean-
ingful improvements in survival statistics for patients with
malignant brain tumors have not been realized in over
thirty years of clinical research [14]. New strategies which
circumvent the limitations of conventional brain tumor
treatments must be conceived, tested and applied to this
devastating disease. One such emerging strategy is to use
the tumor-tracking capacity apparently inherent in many
stem cell (As defined by their capacity of self-renewal and
multipotency) populations tested to identify, track and
potentially effect therapeutic modulation of the brain
tumor microenvironment [15], lessening the reliance on
the current treatment methods [16-18]. Potential stem cell
populations for clinical application include hematopoi-
etic stem cells, human brain-derived neural stem cells
(NSC), bone marrow-derived mesenchymal stem cells
(MSC), embryonic stem cell-derived human NSC (eNSC),
umbilical cord blood derived stem cells, and human
amniotic fluid stem cell. Several intrinsic issues in embry-
onic stem cell therapy include: 1) wide ranging ethical
consideration; 2) the availability of these cells for clinical
use are limited; and 3) immunosuppression is required
for successful engraftment, which may compromise over-
all patient conditions.
The emerging evidence shows a promising result for use of
stem cells for the treatment of brain cancers. Aboody and
colleagues were the first to demonstrate that neural stem
cells (NSC), when implanted into experimental intracra-
nial gliomas in vivo in adult rodents, target themselves
throughout the tumor bed [19]. The implanted NSC
migrates through normal tissue targeting the distantly
implanted tumor cells. When implanted outside the CNS
intravascularly, NSC can also target an intracranial tumor.
As such, the intracranial and intravenous administration
of inherently migratory NSC may be used as a delivery
vehicle for targeting therapeutic agents to modulate brain
tumors. It was shown that the endogenous NSC were spe-
cifically activated and mobilized into an intracranial
tumor while such migratory activity was not observed in
the setting of other nonneoplastic lesions [20,21]. More
importantly, inherent anti-tumor properties within NSC
themselves was reported: Exogenously administered
unmodified NSC inhibited glioma proliferation in vivo
and conditioned medium from NSC suppressed the pro-
liferation of tumor GL261 cells in vitro [22].
Marrow stem cells (MSC) are good candidates for such a
cell-based therapy in human. The main advantages of
using MSC for replacement therapy are that MSC: a) are
the readily accessible and large quantities can be harvested
using patient's own stem cells (autologously) for future
clinical applications, b) can be genetically modified with
therapeutic genes with high efficiency without loss of
stem cell capacity, c) support sustained expression for spe-
cific therapeutic proteins, d) support auto-transplanta-
tion, not requiring immunosuppression; and e) are
generally not subject to ethical concerning like those asso-
ciated with the use of human embryonic stem cells or fetal
neuronal stem cells. In fact, MSC shows an extensive tro-
pism to gliomas, which actively attract MSC by secreting a
multitude of angiogenic and chemotactic cytokines IL-8,
TGF-β1, NT-3, SDF-1, and VEGF [23-25]. Studeny's group
pioneered to demonstrate that MSC can be integrated into
the tumor architecture, which inhibit tumor growth in vivo
by local production of an anti-tumor molecule interferon
(IFN-β) transduced in the MSC [26]. Such an MSC-
assisted targeting delivery of IFN-β to the tumor bed may
be advantageous because the excessive toxicity associated
with systemic administration at effective doses limits its
use as a clinically viable therapeutic modality. Strikingly,
this prediction was confirmed by an observation that sig-
nificantly extending length of survival of mice harboring
human gliomas is achieved with transplanted MSC carry-
ing IFN-β gene but not with intravenous injection of IFN-
β. It appears that MSC can track down not only the main
tumor mass but tumor satellites infiltrated deep into nor-
mal neural tissue [27].Cancer Cell International 2008, 8:9 http://www.cancerci.com/content/8/1/9
Page 3 of 11
(page number not for citation purposes)
Clinical trials using adjuvant stem cells for 
treatment of pediatric brain tumors
Current clinical application of stem cells is considered as
part of combination treatment of brain tumors of using
surgical, chemotherapy and radiation therapy to rejuve-
nate blood and immune systems. Only limited complete
data sets are available currently even though autologous
hematopoietic stem cell transplantation (AHSCT) has
been advocated as a form of salvage therapy for children
with high-risk or relapsed brain tumors for decades [28].
Worldwide there are 38 registered stem cell-based clinical
trials for variety of pediatric brain and central nerve sys-
tem (CNS) tumors; most of which are in Phases I/II (see
the Additional file 1). Majority of these trials are for intra-
venous administration of autologous transplants using
bone marrow and peripheral blood derived stem cells and
only one study (NCT00005796) is conducted with in vitro
treated peripheral blood stem cells, which are Fibronec-
tin-assisted, retroviral-mediated modification of CD34+
PBSC carrying O6-methylguanine DNA methyltransferase.
The rationale for using the stem cell is not to directly target
the tumor but to replace immune cells that were destroyed
by chemotherapy.
In the Schneider Children's Medical Center of Israel Rabin
Medical Center (NCT00607984), patients with metastatic
and relapsed brain tumors were treated with a high-dose
chemotherapy (HDC) followed by autologous stem cell
transplantation (ASCT) as the consolidation therapy. A
large randomized study in children with high risk neurob-
lastoma showed that application of autologous stem cell
transplant can lead to improved disease free and overall
survival, effects that were further augmented by the
administration of biological agents with specific activity
against this tumor. Smaller non-controlled studies and
case series have shown that ASCT is feasible in children
with solid tumors or with tumors of the central nervous
system.
A major limitation of many high-dose chemotherapy
(HDC) protocols, experimental gene therapies, and bio-
logic therapies is that the administered agents are unable
to traverse the blood brain barrier (BBB) in order to reach
the site of the tumor. Thiotepa, a highly myeloablative
bifunctional alkylating agent, was considered a major
breakthrough in the application of high dose chemother-
apies in children with CNS tumors because it partitions
equally across the BBB. Thiotepa remains a mainstay of
HDC protocols for children with CNS tumors. As such,
combining chemotherapy with peripheral stem cell trans-
plantation may allow the doctor to give higher doses of
chemotherapy drugs and kill more tumor cells. Similarly,
TEMOZOLOMIDE (Temodor) is the American Food and
Drug Administration (FDA) approved for grade III ana-
plastic astrocytoma based largely on low side effects pro-
file and excellent CNS penetration. Preliminary studies
suggest that stem cells can cross BBB to reach brain tumors
targets. Alternatively, therapeutic stem cells population
can be directly introduced via stereotactic injection into
the CNS tumor tissue.
Cheuk and colleagues report the long-term effects of
AHSCT treatment for 13 pediatric brain tumor patients for
a period of 10 years (1996–2006) in Hong Kong, includ-
ing medulloblastoma (n = 9), cerebral primitive neuroec-
todermal tumor (n = 1), ependymoma (n = 1), germ cell
tumor (n = 1) and cerebellar rhabdoid (n = 1) with tumor
residual (n = 1) or recurrence (n = 12). Prior to AHSCT, 8
patients (61.5%) achieved complete remission and 5
(38.5%) were in partial remission with conditioning
employed thiotepa, etoposide and carboplatin. Adverse
effects of mucositis and neutropenic fever in all patients,
grade 4 hepatic toxicity in 4 patients and grade 4 renal tox-
icity in 1 patient were observed associated with the chem-
otherapy. The results with AHSCT in the study include: 1)
The 5-year event-free survival was 53.9%; 2) Five patients
died of disease recurrence or progression 8–21 months
after transplant with a median disease-free period of 8
months post-transplant; 3) One died of transplant-related
complications in the early post-transplant period; 4)
Seven survived for a median of 5.4 years (maximum fol-
low-up of 9.8 years), with 6 having Lansky-Karnofsky per-
formance score above 80; 5) All survivors had complete
remission before transplant though 2 had leptomeningeal
spread [28]. It appears that AHSCT can empower long-
term survival in children with recurrent brain tumor, how-
ever; those patients with macroscopic residual tumors
before the transplant could not be salvaged.
Nonetheless, controversial efficacies raised doubt about
the clinical benefits of conventional stem cell therapy. The
efficacy can be fluctuated by many factors including the
quality of the stem cell (number of effective stem cell sub-
population, the differentiation status, and the age of the
stem cell), the occurrence of graft versus host reaction,
overall survival, disease free survival and immune recov-
ery [18]. Some of these efficacious variations may stem
from the biological differences related to a cancer or treat-
ment of interest. Others, however, may reflect the hetero-
geneity of patients across multiple sites, the inherent
biological complexity and diversity of different cancer
types, and even small differences in stem cell preparation,
processing, handling, and analysis techniques used by
multiple operators across multiple locations. As a conse-
quence, data may be differed by site-, study-, population-
, or sample-specific anomalies and, therefore, not be suf-
ficiently robust for making a concrete conclusion. There is
an urgent need for development of a uniform technicalCancer Cell International 2008, 8:9 http://www.cancerci.com/content/8/1/9
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platform to clarify the ultimate clinical viability of stem
cell therapy for brain tumors.
Mechanism of action for stem cell therapy of 
brain tumors
Although stem cells show certain level of therapeutic ben-
efits, little is known about mechanisms by which stem
cells eradicate tumor cells by use of stem cell homing and
migration toward the tumor. Stem cells may directly mod-
ulate the tumor microenvironment via their therapeutic
effects of regenerative potential, neurotrophic and neuro-
protective properties, and immune regulatory functions
(e.g., inhibit the cellular inflammatory process in the
tumor) [29,30]. Human MSC transcriptome analyses
reveal that MSC transplanted at sites of nerve injury pro-
mote functional recovery by producing trophic factors
that induce survival and regeneration of host neurons,
including BDNF and β-NGF, various neurite-inducing fac-
tors, axon guidance and neural cell adhesion molecules
[31].
Some examples of therapeutic strategies such as gene or
drug delivery systems using stem cell homing show an
anti-cancer efficacy, including EGFR antagonist, IL-2, IL-4
cytotoxin, interleukin-13 receptor-directed cytotoxin [32],
BMP-1/-2, IFN-β, TNFα [33]. Intriguingly, efficacy was
shown in three stem cell types tested, including brain-
derived mouse neural stem cells (mNSC), brain-derived
human NSC (hNSC), and embryonic stem cell-derived
human NSC (eNSC) for treatment of neurometabolic dis-
orders in the animal model [34]. No efficacy was shown
in human fibroblasts, which stayed in the local injection
site, suggesting that efficacious cell populations must pos-
sess the inherited physiologically-relevant properties such
as the migrate capacity toward inflammation. Despite
these exciting reports, many scientists have difficulties in
duplicating the similar anti-tumor effects of NSC in their
laboratories. It is possible that this property may vary with
the source, method of preparation, differentiation status,
and age of the stem cells. A screening platform is required
to isolate and expand such a potent anti-cancer sub-pop-
ulation of the stem cell with the targeting capacity for clin-
ical application.
Current knowledge and unanswered questions 
in development of stem cells for targeting 
therapy of brain tumors using the conventional 
tissue culture and animal models
Despite exciting initial reports, clinical potency of stem
cell therapy in animal brain tumor models has to date
proven disappointing. Attempts to extrapolate current
results to humans arrive at discouraging and impractical
protocols. Indeed, some initial attempts to apply of
human disease by embryonic stem cell therapy have
proven dangerous to the subject, e.g., induced the forma-
tion of heterogeneous tumors and trigged inflammation.
However, with optimization of clinically relevant param-
eters (enrichment and expansion of functional stem cell
populations, improved recruitment and activation of clin-
ically relevant stem cell populations, enhancement of tar-
geted migration, and augmentation of therapeutic
potency of targeted stem cells), realistic clinical protocols
are anticipated.
Beside ethical and immunologic concerns associated with
the use of fetal-derived tissue as a stem cell source, the
problem is that lack of uniform platform in current stem
cell research leads to an inconsistent efficacy. It takes a
long time to select an effective tumor-tracking sub-popu-
lation of the stem cell, even more challenge to optimize a
new therapy with current workflow (Figure 1). The current
technique includes determination of the source of work-
ing stem cells (MSC, NSC, eNSC), the selection of culture
media, the state of stem cell cycle (undifferentiated vs. dif-
ferentiated), the mode of culture (adhere vs. suspension),
the form of growth (neurosphere vs. monolayer), sub-
strate variations (Fibronectin, laminin, or Matrigel) and
using different animal models to test each therapeutic var-
iation, each possible way of using different stem cells
(MSC, NSC, eNSC) to treat different brain cancers. An
additional and very troublesome problem is that once
stem cells are introduced into the animal, they become
very difficult to track as they blend in with the animal tis-
sue, since they are not an organ and they are very small. It
becomes difficult to determine, exactly, where the cells are
going and what the cells are doing. It is not uncommon
that millions of stem cells are used for transplantation,
however; only a tiny fraction of the stem cell is found in
the target injury tissue [35]. As such, clinical progress is
greatly hindered by current scheme of using in vitro assays
and animal models, which result in inconsistent effica-
cies.
An innovative organotypic slice platform for 
evaluation of stem cell potential to targeting 
brain tumor
Targeting competency of stem cells is a quintessential
stepping stone to successful stem cell therapy of brain
tumors, however; only a fraction of cultured stem cells
possess such a chief characteristics in stem cells prepared
with conventional work flow (Figure 1) [36]. Our pro-
posed workflow allows us to much more quickly identify
and abandon techniques and stem cell populations that
do not work and arrive at techniques and cell populations
that do (Figure 1). We have established a platform tech-
nology, which is a much more efficient approach, namely
"living test dish" (patent pending) or "brains in a dish" for
selection of stem cell sub-populations capable of targeting
brain tumors (Figure 2). The living test dish consists of
organotypic slices that are micrometers thick of an animalCancer Cell International 2008, 8:9 http://www.cancerci.com/content/8/1/9
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organ, which are cultured under conditions in which the
slice retains the cellular composition, morphology, and
the physiological properties of the in situ source organ
(Figure 3). The slice model presents a major advantage
over using traditional in vitro cell culture methods and in
vivo models (Table 1). By using living slices that viability
of the slice can be maintained for many months, we can
introduce stem cells into to these living "brains in a dish,"
determine cell populations in a real-time fashion. In this
platform, we can serially manipulate and determine the
parameters optimal for targeting brain tumors in a rela-
tively short period of time before actually moving into
experiments in the whole animal. This platform also
allows us to use far fewer animals. Importantly, we believe
that this organotypic slice-based approach lends itself to
applications for a wide variety of other brain diseases and
diseases of other organs of the body as well.
Alternatively, an innovative organotypic slice system can
be generated from a modified cellular component, a mod-
ified extracellular matrix component, a modified genetic
component, or a combination thereof. For example, in the
central nervous system, the extracellular matrix influences
the interactions of neuronal cells and glial cells; and, it
also regulates cell migration, cell survival, cell differentia-
tion, axonal growth, and synapse formation. Such organ-
otypic slice can be derived from a transgenic, mutant, null,
gain-of-function, loss-of-function, knock-in, or knockout
animals. The modified organotypic slice system can be
used to dissect how implanted stem cells interact with res-
ident cellular matrix and injured residential cells to pre-
dict how stem cells behave in vivo.
Application of the organotypic slice platform for 
determination of targeting capacity of stem cells
For example, research efforts show that two properties of
stem cell functional activity are critical: the ability of the
stem cell to detect a target (homing) and the ability of the
stem cell to track and migrate through the tissue to its tar-
get (matrix-remodeling) for their integration and differen-
tiation to foci of intracranial glioma [36]. These two
functions have been used interchangeably but they are
A workflow chart for development of stem cell sub-populations capable of targeting brain tumors for clinical application Figure 1
A workflow chart for development of stem cell sub-populations capable of targeting brain tumors for clinical application. CR: 
Chemokine receptor; HST: High throughput screening; MMPs: Metal metalloproteases; 3D: Three-dimensional culture. Dash 
line: Current workflow. Solid line: our proposed workflows.Cancer Cell International 2008, 8:9 http://www.cancerci.com/content/8/1/9
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distinct and equally important. Homing appears to be
mediated to a large extent by the secretion of chemokines
into the tumor microenvironment and the expression of
chemokine receptors on the stem cells [37]. The essential
driving force for stem cell migration toward brain tumors
is the binding chemokine (e.g., SDF-1) to its chemokine
receptor (e.g., CXCR4) that mediates the signal transduc-
tion (Figure 4). Matrix remodeling appears to be medi-
Table 1: Comparison of Three Test Systems: In vitro, ex vivo, and in vivo model.
In Vitro Animal Model Living Test Tube
Cost Effective + + + - - - + +
Realistically Mimic In Vivo - - - + + + + + +
Assay Multiple Time Points + + + -/+ + + +
3 Dimensional Integration - - - + + + + +
Real-Time Monitor + + - - + + +
High Throughput Screening + + + - - - + +
Ethical (Animal) + + + - - - +
Schematic diagram for model systems of studying brain stem cells including in vitro, ex vivo and in vivo Figure 2
Schematic diagram for model systems of studying brain stem cells including in vitro, ex vivo and in vivo.Cancer Cell International 2008, 8:9 http://www.cancerci.com/content/8/1/9
Page 7 of 11
(page number not for citation purposes)
ated, at least in part, by the secretion of matrix
metalloproteinases by the stem cell [38]. Independent,
but coordinated, regulation of these two functional
behaviors of stem cells (therapeutic activation) must
occur for these cells to be of any therapeutic competency.
Our data argue for the requirement of "appropriate" extra-
cellular matrix environment for optimal metalloprotein-
ase expression (Manuscript in preparation).
Little is known about how we can effectively activate and
program the stem cell migration for stem cell transplanta-
tion although it is known that regulators of migration
include MMPs, elastases, c-kit, and stem cell factor which
govern the expression of SDF-1 and CXCR-4 [36]. For
example, quiescent stem cell populations minimally
express chemokine receptors, which are not sufficient for
any therapeutic success [39,40]. To compound the prob-
lem, different culture conditions affect the migratory
parameters and migration pattern [41,42]. The further
selection of a migratory stem cell sub-population necessi-
tates a platform technology to identify and manipulate a
"therapeutic migratory state" that addresses a potential
window of opportunity when stem cells are the most
effective to target brain tumors. A work flow for selection
of both stem cell sub-population and their activation sta-
tus is a quintessential stepping stone for any therapeutic
success.
We postulate that an organotypic slice-based platform
integrated with a workflow from an in vitro three dimen-
sional extracellular milieu model (3D), an ex vivo organo-
typic brain slice model to the in vivo animal model
ultimately can be used for selection of therapeutic migra-
tory stem cell sub-population and their activation state
(Figure 1). The platform of using organotypic slice can val-
idate how temporal expression levels of chemokine recep-
tors of the stem cells can be quantitatively correlated with
the capacity of migration toward to brain tumor-produced
signal ligand SDF-1. We can test experimentally this work-
flow paradigm. The foundation of this experimental plat-
form is to establish a system mimic in vivo, first to
maintain stem cells in a quiescent state, and then induce
stem cells to produce targeting molecule cytokine recep-
tors and matrix remodeling enzymes. We can show that
Stem cells showing tropism for malignant tumor cells implanted on rodent organotypic slice model Figure 3
Stem cells showing tropism for malignant tumor cells implanted on rodent organotypic slice model. An organotypic slice is 
derived from a central nervous system tissue of an organism, indicating that the central nervous system tissue is sliced at a 
boundary such that an endogenous fiber tract of the central nervous system tissue is intact, through which the stem cell 
migrate toward the CNS tumor. Scheme is based on [15].Cancer Cell International 2008, 8:9 http://www.cancerci.com/content/8/1/9
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stem cells remain quiescent without SDF-1 in three-
dimensional culture. In the presence of SDF-1, stem cells
are induced to produce MMP-9 and CXCR4. One critical
issue is to determine if CXCR4 expression levels correlate
with stem cell migration toward SDF-1 concentration gra-
dients. Our data indicate that migration of neural stem
cells is enhanced by an intermediate concentration of
SDF-1 gradient but inhibited by higher concentrations,
with no stimulation at low concentrations (Manuscript in
preparation). These results may suggest that SDF-1 gradi-
ents may coordinate the stop and start signals for regulat-
ing stem cell migration. Another critical issue, assuming
that receptor expression affects migration, asks whether
CXCR4 expression in stem cells can be experimentally and
even clinically manipulated. Our data indicates that
CXCR4 mRNA and surface receptor expression increases
with defined cultured medium and conditions (Manu-
script in preparation).
The ultimate criterion is to test that expression scale of
CXCR4 correlates the stem cell capacity of targeting brain
tumors in vivo. Our hypothesis is that ex vivo brain hippoc-
ampus slice mimic brain structure better than 3D extracel-
lular matrix model. Here we have established an ex vivo
system, namely rat brain hippocampus slice model, which
mimic the in vivo brain structure and microenvironment
(Figure 4). This system shows that it can support migra-
tion and growth, maintain the survival of stem cells,
migrate toward brain tumor cells and drive their differen-
tiation for 30 days (Figure 5), which enable us to study
how stem cells target the brain tumor cells. The large
dimension with intact fiber track of rat brain hippocam-
pus slice allows detailed mapping the stem cell targeting
pathways (Figure 4). This observation can be evaluated in
vivo animal brain tumor model coupled with a real-time
tracking system [43].
Implication of using organotypic slice platform
Lack of a standardized platform for evaluation of stem cell
capacity to target brain tumors may contribute to contro-
versial and inconsistent results. Organotypic slices have
the advantage of being easier to use and manipulate than
Model of SDF-1-mediated signal transduction for targeting of stem cells toward brain tumor Figure 4
Model of SDF-1-mediated signal transduction for targeting of stem cells toward brain tumor. Brain tumors release SDF-1 gradi-
ent into the tumor microenvironment. Binding SDF-1 to its receptor expressed in stem cells triggers the signal transduction 
pathways that lead to cytoskeletons reorganization, which drives stem cell migration toward brain tumor microenvironment. 
CXCR-4: chemokine (C-X-C motif) receptor 4, a.k.a., SDF-1 receptor or CD184; SDF-1: stromal cell-derived factor-1 (chem-
okine), a.k.a., CXCL12 (see [37]).Cancer Cell International 2008, 8:9 http://www.cancerci.com/content/8/1/9
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in vivo models such as rodents and primates. Moreover,
modified organotypic slice systems allow cellular and
molecular assessment, which enables, for example, the
identification of factors that control neuronal adhesion,
acquisition of cell-specific phenotypes, regulation of
axonal and dendritic patterning, and development of
tumor diseases. Organotypic slices may also be used to
study cell migration, cell differentiation, cell-induced tis-
sue injury repair, or even cell susceptibility to drugs. Based
upon our preliminary studies, we postulate that a novel
stem cell "therapeutic activation state" that is effective for
targeting brain tumors can be thoroughly determined by
defining associated molecular, biochemical and biologi-
cal events with an innovative modified organotypic slice
system. Establishment of such a standardized platform
technology will enable the rapid evaluation of stem cell
potential for targeting specific pediatric brain tumors as
well as other pathological conditions.
In addition, the proposed platform can be integrated into
a work flow to program stem cells to become a clinically
relevant stem cell sub-population capable of homing and
migration toward tumors (Figure 1). We can determine
the migratory parameters by using in vitro, ex vivo, and in
vivo tumor models. Stem cell migration can be critically
assessed with physiologically relevant chemokine gradi-
ents utilizing microfabricated fluidic chamber systems. Ex
vivo  correlation of chemokine receptors and matrix
remodeling capacity can be determined using our innova-
tive organotypic slice microenvironment by which the
organ-like microenvironment within the fresh human
brain tumor microenvironment can be reconstructed with
a real-time monitor. These results can be compared to in
vivo intracranial brain tumor xenograft models in immu-
nosuppressed mice. The organotypic slice cultures can be
used to facilitate the several real-time assessments of cel-
lular, molecular, phenotypic, biochemical, and develop-
ment characteristics, which enable, for example, the
identification of factors that control stem cell adhesion,
acquisition of cell-specific phenotypes, and regulation of
axonal and dendritic patterning, integration and engraft-
ment of stem cells within tumors. Organotypic slices may
also be used to study cell migration, cell differentiation,
cell-induced tissue injury repair, or even cell susceptibility
to therapeutics.
Perspectives and future directions
Emerging evidence indicates that stem cells may be a rev-
olutionary therapy for treatment of malignant brain
tumors compared with traditional therapies of chemo-
therapy, radiotherapy and surgery. However, current tech-
nologies unfortunately do not consistently deliver the
potential clinical benefits of stem cell transplantation for
targeting treatment of brain tumors. To begin to unravel
the biological behavior of stem cells, we have proposed a
conceptual ex vivo organotypic slice platform to specifi-
cally select stem cell sub-population for targeting brain
tumors, which complements the design of traditional in
vivo  animal model studies. Within this experimental
framework, data showing the myriad of factors in regulat-
ing the complex targeting and migration pattern will
shape the traditional biological models. Information
obtained will allow us to further explore the detailed
mechanisms underlying the perspective roles of stem cell
migration for targeting brain tumors. Advances in diagno-
sis and treatment of childhood cancers are expected to
emerge from these coordinated stem cell studies, hope-
fully culminating in better cancer survival prognosis with
a reduction in the risks of acute and late adverse conse-
quences of current treatment.
Rat brain organotypic slice can support stem cell survival and migration toward human tumor cells Figure 5
Rat brain organotypic slice can support stem cell survival and migration toward human tumor cells. A: Part of rat brain slice 
showing the implantation site (arrow) of GFP labeled neural stem cells (NSC) (phase contrast, 4×). B: Same field as (A) under 
fluorescence illumination showing the implanted cells (arrow). C: As early as 1 hour of implantation, NSC migrated out of the 
initial site toward a remotely implanted brain tumor site (not shown); D Live imaging of NSC 30 days after implantation indicat-
ing that NSC survived at least 30 days on the slice (40×).Cancer Cell International 2008, 8:9 http://www.cancerci.com/content/8/1/9
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